{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T05:41:58Z","timestamp":1741153318593,"version":"3.38.0"},"reference-count":34,"publisher":"Oceanside Publications Inc.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:p><jats:bold>Backround:<\/jats:bold> Rapid drug desensitization (RDD) is commonly used for immediate drug hypersensitivity reactions (DHR) across various drugs. In delayed DHRs, the conventional approach is slow desensitization; however, limitations may arise due to drug-specific or disease-related\n factors. With the increasing role of targeted molecular drugs in delayed DHRs, data on the efficacy of RDD in these contexts remain scarce.  <jats:bold>Objective:<\/jats:bold> This case series aims to explore the rationale and outcomes of RDD in managing delayed DHRs associated with targeted therapies.\n  <jats:bold>Methods:<\/jats:bold> We analyzed data from patients referred to a tertiary university hospital's drug allergy outpatient clinic between January 2021 and April 2024. The subjects experienced delayed DHRs during treatment with targeted drugs and, subsequently, underwent RDD.  <jats:bold>Results:<\/jats:bold>\n The drugs administered via RDD included bevacizumab, rituximab, daratumumab, lenalidomide, bortezomib, and carfilzomib. The index reactions included maculopapular eruptions (MPE), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis\n (AGEP). Delayed breakthrough reactions were observed in four of seven patients. RDD with bortezomib was unsuccessful in all three patients, and delayed reactions were observed in all patients with severe cutaneous adverse reactions (AGEP and DRESS).  <jats:bold>Conclusion:<\/jats:bold> Suggesting\n significant success of RDD for delayed DHRs induced by targeted therapies may be overly optimistic. Nevertheless, four of seven patients, including one with AGEP, were able to continue their treatment. Managing patients with advanced diseases and delayed DHR poses notable challenges. The risk\n to patient survival from withholding life-saving medication must be weighed against the risks of desensitization. The low sensitivity of skin tests and the critical waiting period complicate decision-making. Given the unique contribution of targeted agents in the treatment of severe, life-threatening\n diseases, further research on desensitization is warranted.<\/jats:p>","DOI":"10.2500\/aap.2025.46.240101","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T04:31:02Z","timestamp":1740630662000},"page":"e70-e77","source":"Crossref","is-referenced-by-count":0,"title":["Rapid drug desensitization in seven patients with delayed hypersensitivity reactions to biologics and targeted therapies: Reason, successes, and failures"],"prefix":"10.2500","volume":"46","author":[{"given":"Tugba","family":"Onalan","sequence":"first","affiliation":[{"name":"From the Division of Clinical Immunology and Allergy, Department of Internal Medicine, Necmettin Erbakan University, Meram Faculty of Medicine, Konya, Turkey and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatih","family":"Colkesen","sequence":"additional","affiliation":[{"name":"From the Division of Clinical Immunology and Allergy, Department of Internal Medicine, Necmettin Erbakan University, Meram Faculty of Medicine, Konya, Turkey and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Emin","family":"Gerek","sequence":"additional","affiliation":[{"name":"From the Division of Clinical Immunology and Allergy, Department of Internal Medicine, Necmettin Erbakan University, Meram Faculty of Medicine, Konya, Turkey and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatma Arzu","family":"Akkus","sequence":"additional","affiliation":[{"name":"From the Division of Clinical Immunology and Allergy, Department of Internal Medicine, Necmettin Erbakan University, Meram Faculty of Medicine, Konya, Turkey and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Recep","family":"Evcen","sequence":"additional","affiliation":[{"name":"Division of Clinical Immunology and Allergy, Department of Internal Medicine, Recep Tayyip Erdo\u011fan University, Faculty of Medicine, Rize, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevket","family":"Arslan","sequence":"additional","affiliation":[{"name":"From the Division of Clinical Immunology and Allergy, Department of Internal Medicine, Necmettin Erbakan University, Meram Faculty of Medicine, Konya, Turkey and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1111\/all.14810","article-title":"Medical algorithm: diagnosis and treatment of hypersensitivity reactions to cancer chemotherapy","volume":"76","author":"Madrigal-Burgaleta","year":"2021","journal-title":"Allergy"},{"key":"B2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pediatrneurol.2014.03.021","article-title":"Human leukocyte antigen genotypes and trial of desensitization in patients with oxcarbazepine-induced skin rash: a pilot study","volume":"51","author":"Lee","year":"2014","journal-title":"Pediatr Neurol"},{"key":"B3","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/all.12161","article-title":"Desensitization in delayed drug hypersensitivity reactions \u2013 an EAACI position paper of the Drug Allergy Interest Group","volume":"68","author":"Scherer","year":"2013","journal-title":"Allergy"},{"key":"B4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000078583","article-title":"Successful desensitization to fixed drug eruption: the presence of CD25+CD4+ T cells in the epidermis of fixed drug eruption lesions may be involved in the induction of desensitization","volume":"209","author":"Teraki","year":"2004","journal-title":"Dermatology"},{"key":"B5","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0091-6749(03)01624-5","article-title":"IFN-gamma-producing effector CD8+ T cells and IL-10-producing regulatory CD4+ T cells in fixed drug eruption","volume":"112","author":"Teraki","year":"2003","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.5415\/apallergy.2019.9.e9","article-title":"Interleukin-10 is increased in successful drug desensitization regardless of the hypersensitivity reaction type","volume":"9","author":"Gelincik","year":"2019","journal-title":"Asia Pac Allergy"},{"key":"B7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijid.2018.01.006","article-title":"Successful drug desensitization in patients with delayed-type allergic reactions to anti-tuberculosis drugs","volume":"68","author":"Siripassorn","year":"2018","journal-title":"Int J Infect Dis"},{"key":"B8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/0897190018756237","article-title":"Successful phenobarbital desensitization after DRESS reaction in the management of refractory status epilepticus","volume":"32","author":"Witcher","year":"2019","journal-title":"J Pharm Pract"},{"key":"B9","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/bjh.12925","article-title":"Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma","volume":"167","author":"Lee","year":"2014","journal-title":"Br J Haematol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11882-022-01052-z","article-title":"Utilizing biologics in drug desensitization","volume":"23","author":"Yang","year":"2023","journal-title":"Curr Allergy Asthma Rep"},{"key":"B11","doi-asserted-by":"crossref","first-page":"786863","DOI":"10.3389\/falgy.2021.786863","article-title":"Use of rapid drug desensitization in delayed hypersensitivity reactions to chemotherapy and monoclonal antibodies","volume":"2","author":"Vega","year":"2022","journal-title":"Front Allergy"},{"key":"B12","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.jaip.2021.12.041","article-title":"Successful rapid desensitization to atezolizumab in delayed hypersensitivity confirmed with lymphocyte transformation test","volume":"10","author":"Giraldo-Tugores","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2500\/aap.2017.38.4085","article-title":"Management of adverse reactions to biologic agents","volume":"38","author":"Isabwe","year":"2017","journal-title":"Allergy Asthma Proc"},{"key":"B14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11523-008-0102-9","article-title":"Targeted therapies in multiple myeloma","volume":"4","author":"Kastritis","year":"2009","journal-title":"Target Oncol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/all.13735","article-title":"Delayed drug hypersensitivity to bortezomib: desensitization and tolerance to its analogue carfilzomib","volume":"74","author":"Galvan-Blasco","year":"2019","journal-title":"Allergy"},{"key":"B16","first-page":"448","article-title":"Rapid desensitization with temozolomide in patients with delayed maculopapular rash","volume":"22","author":"Alonso-Llamazares","year":"2012","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4103\/ijd.IJD_581_17","article-title":"Acute generalised exanthematous pustulosis: an update","volume":"63","author":"De","year":"2018","journal-title":"Indian J Dermatol"},{"key":"B18","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jaci.2008.02.044","article-title":"Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases","volume":"122","author":"Castells","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/eci.11.75","article-title":"Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies","volume":"8","author":"Hong","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"100673","DOI":"10.1016\/j.waojou.2022.100673","article-title":"DRESS syndrome: a literature review and treatment algorithm","volume":"16","author":"Calle","year":"2023","journal-title":"World Allergy Organ J"},{"key":"B21","doi-asserted-by":"crossref","first-page":"344","DOI":"10.18176\/jiaci.0982","article-title":"Rapid drug desensitization protocol in delayed hypersensitivity reactions to CFTR modulator drugs: when every day counts","volume":"34","author":"Rodr\u00edguez-Otero","year":"2024","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.rmed.2018.12.017","article-title":"Efficacy and tolerability of desensitization in the treatment of delayed drug hypersensitivities to anti-tuberculosis medications","volume":"147","author":"Ban","year":"2019","journal-title":"Respir Med"},{"key":"B23","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/ijcp.12097","article-title":"The cutaneous adverse drug reactions: risk factors, prognosis and economic impacts","volume":"67","author":"Liao","year":"2013","journal-title":"Int J Clin Pract"},{"key":"B24","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s12016-021-08872-3","article-title":"Sulfonamide hypersensitivity","volume":"62","author":"Chow","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"B25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4236\/oji.2013.33019","article-title":"Activating interactions of sulfanilamides with T cell receptors","volume":"3","author":"Watkins","year":"2013","journal-title":"Open J Immunol"},{"key":"B26","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.amjmed.2008.04.016","article-title":"Allopurinol hypersensitivity and DRESS syndrome","volume":"121","author":"Markel","year":"2008","journal-title":"Am J Med"},{"key":"B27","doi-asserted-by":"crossref","first-page":"573573","DOI":"10.3389\/fphar.2020.573573","article-title":"An updated review of the diagnostic methods in delayed drug hypersensitivity","volume":"11","author":"Copaescu","year":"2020","journal-title":"Front Pharmacol"},{"key":"B28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jaip.2022.09.011","article-title":"Utility and safety of skin tests in drug reaction with eosinophilia and systemic symptoms (DRESS): a systematic review","volume":"11","author":"Teo","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B29","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.12125","article-title":"A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions","volume":"168","author":"Barbaud","year":"2013","journal-title":"Br J Dermatol"},{"key":"B30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0536.2009.01659.x","article-title":"Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS)","volume":"62","author":"Santiago","year":"2010","journal-title":"Contact Dermatitis"},{"key":"B31","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.3390\/ijms19124090","article-title":"How glucocorticoids affect the neutrophil life","volume":"19","author":"Ronchetti","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00441-017-2774-x","article-title":"A head-to-tail view of L-selectin and its impact on neutrophil behaviour","volume":"371","author":"Ivetic","year":"2018","journal-title":"Cell Tissue Res"},{"key":"B33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1081-1206(10)62474-X","article-title":"A 5-day course of oral desensitization to trimethoprim\/sulfamethoxazole (T\/S) in patients with human immunodeficiency virus type-1 infection who were previously intolerant to T\/S","volume":"85","author":"Yoshizawa","year":"2000","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B34","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ejh.13918","article-title":"Desensitization protocol to lenalidomide: an effective and safe treatment modality for delayed hypersensitivity-induced rash in patients with multiple myeloma","volume":"110","author":"Shamriz","year":"2023","journal-title":"Eur J Haematol"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2025\/00000046\/00000002\/art00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T04:34:44Z","timestamp":1741149284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2025.46.240101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3,1]]}},"alternative-id":["1088-5412(20250301)46:2L.70;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2025.46.240101","relation":{},"ISSN":["1088-5412"],"issn-type":[{"type":"print","value":"1088-5412"}],"subject":[],"published":{"date-parts":[[2025,3,1]]}}}